Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant

Boyce, 2000, Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults, Vaccine, 19, 217, 10.1016/S0264-410X(00)00171-7 Moschos, 2004, Adjuvant synergy: the effects of nasal coadministration of adjuvants, Immunol Cell Biol, 82, 628, 10.1111/j.0818-9641.2004.01280.x Han, 2006, Thermosensitive and mucoadhesive delivery systems of mucosal vaccines, Methods, 38, 106, 10.1016/j.ymeth.2005.10.003 Pun, 2009, Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses, Int Immunopharmacol, 9, 468, 10.1016/j.intimp.2009.01.012 van Ginkel, 2000, Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues, J Immunol, 165, 4778, 10.4049/jimmunol.165.9.4778 Schulze, 2003, Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein, Vaccine, 21, 1958, 10.1016/S0264-410X(02)00803-4 Cavallo, 2005, An integrated approach of immunogenomics and bioinformatics to identify new tumor associated antigens (TAA) for mammary cancer immunological prevention, BMC Bioinformatics, 4, S7, 10.1186/1471-2105-6-S4-S7 Guy, 2005, New adjuvants for parenteral and mucosal vaccines, Therapie, 60, 235, 10.2515/therapie:2005030 Burdin, 2004, Immunological foundations to the quest for new vaccine adjuvants, BioDrugs, 18, 79, 10.2165/00063030-200418020-00002 Di Guilmi, 2002, New approaches towards the identification of antibiotic and vaccine targets in Streptococcus pneumoniae, EMBO Rep, 3, 728, 10.1093/embo-reports/kvf152 Teicher, 2000, Molecular targets and cancer therapeutics: discovery, development and clinical validation, Drug Resist Updat, 3, 67, 10.1054/drup.2000.0123 Lizotte-Waniewski, 2000, Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries, Infect Immun, 68, 3491, 10.1128/IAI.68.6.3491-3501.2000 Tseng, 2010, The influence of liposomal adjuvant on intranasal vaccination of chickens against Newcastle disease, Vet J, 185, 204, 10.1016/j.tvjl.2009.05.019 Freytag, 2005, Mucosal adjuvants, Vaccine, 23, 1804, 10.1016/j.vaccine.2004.11.010 Cataldi, 2008, Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant, Vaccine, 26, 5662, 10.1016/j.vaccine.2008.07.027 Schulze, 2008, A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus, Vaccine, 26, 6678, 10.1016/j.vaccine.2008.09.006 Borsutzky, 2006, Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant, Vaccine, 24, 2049, 10.1016/j.vaccine.2005.11.025 Sun, 2007, TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders, Inflamm Allergy Drug Targets, 6, 223 Jasani, 2009, Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer, Vaccine, 27, 3401, 10.1016/j.vaccine.2009.01.071 Kamijuku, 2008, Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses, Mucosal Immunol, 1, 208, 10.1038/mi.2008.2 Ebensen, 2007, A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties, J Immunol, 179, 2065, 10.4049/jimmunol.179.4.2065 Lycke, 2004, From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM, Cell Microbiol, 6, 23, 10.1046/j.1462-5822.2003.00338.x Guidry, 1997, Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin, Infect Immun, 65, 4943, 10.1128/IAI.65.12.4943-4950.1997 Agren, 1999, Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity, J Immunol, 162, 2432, 10.4049/jimmunol.162.4.2432 Kundu, 2009, Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge, FEMS Immunol Med Microbiol, 56, 179, 10.1111/j.1574-695X.2009.00563.x Cao, 2008, Hantavirus mucosal vaccine through different mucosal with heat-labile enterotoxin B subunit as adjuvants, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 22, 174 Cox, 2006, Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa, Vet Res, 37, 511, 10.1051/vetres:2006014 Hu, 2001, Immunostimulating complexes (ISCOMs) for nasal vaccination, Adv Drug Deliv Rev, 51, 149, 10.1016/S0169-409X(01)00165-X Chen, 2010, Recent advances in the development of novel mucosal adjuvants and antigen delivery systems, Hum Vaccin, 6 Tagliabue, 2008, Vaccine adjuvants: the dream becomes real, Hum Vaccin, 4, 347, 10.4161/hv.4.5.6438 Ross, 1991, Cellulose biosynthesis and function in bacteria, Microbiol Rev, 55, 35, 10.1128/MMBR.55.1.35-58.1991 Miller, 2001, Quorum sensing in bacteria, Annu Rev Microbiol, 55, 165, 10.1146/annurev.micro.55.1.165 Reading, 2006, Quorum sensing: the many languages of bacteria, FEMS Microbiol Lett, 254, 1, 10.1111/j.1574-6968.2005.00001.x Karaolis, 2005, 3’,5’-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation, Biochem Biophys Res Commun, 329, 40, 10.1016/j.bbrc.2005.01.093 Ebensen, 2007, The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant, Clin Vaccine Immunol, 14, 952, 10.1128/CVI.00119-07 Ebensen, 2007, The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties, Vaccine, 25, 1464, 10.1016/j.vaccine.2006.10.033 Karaolis, 2007, Bacterial c-di-GMP is an immunostimulatory molecule, J Immunol, 178, 2171, 10.4049/jimmunol.178.4.2171 Chen, 2010, The potential of 3’,5’-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant, Vaccine, 28, 3080, 10.1016/j.vaccine.2010.02.081 Ogunniyi, 2008, c-Di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection, Vaccine, 26, 4676, 10.1016/j.vaccine.2008.06.099 Libanova, 2010, The member of the cyclic di-nucleotide family bis-(3’,5’)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant, Vaccine, 28, 2249, 10.1016/j.vaccine.2009.12.045 Witte, 2008, Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates, Mol Cell, 30, 167, 10.1016/j.molcel.2008.02.020 Romling, 2008, Great times for small molecules: c-di-AMP, a second messenger candidate in Bacteria and Archaea, Sci Signal, 1, pe39, 10.1126/scisignal.133pe39 Woodward, 2010, c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response, Science, 328, 1703, 10.1126/science.1189801 Robertson, 2000, DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope, J Immunol, 164, 4706, 10.4049/jimmunol.164.9.4706 Barnden, 1998, Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements, Immunol Cell Biol, 76, 34, 10.1046/j.1440-1711.1998.00709.x Hogquist, 1994, T cell receptor antagonist peptides induce positive selection, Cell, 76, 17, 10.1016/0092-8674(94)90169-4 Murphy, 1990, Induction by antigen of intrathymic apoptosis of CD4+ CD8+ TCRlo thymocytes in vivo, Science, 250, 1720, 10.1126/science.2125367 Hsu C.-Y.J., 1985, Synthesis and physical characterization of Bis 3’,5’ cyclic dinucleotides (–NpNp–): RNA polymerase inhibitors, Nucleosides Nucleotides, 4, 377, 10.1080/07328318508056168 Ross, 1990, The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives, J Biol Chem, 265, 18933, 10.1016/S0021-9258(17)30606-3 Karaolis, 2007, Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia, Infect Immun, 75, 4942, 10.1128/IAI.01762-06 Muhlradt, 1994, Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6, Infect Immun, 62, 3801, 10.1128/IAI.62.9.3801-3807.1994 Deiters, 2003, Infect Immun, 71, 4456, 10.1128/IAI.71.8.4456-4462.2003 Link, 2004, The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity, Eur J Immunol, 34, 899, 10.1002/eji.200324511 Borsutzky, 2003, Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant, Eur J Immunol, 33, 1548, 10.1002/eji.200323954 Ebensen, 2004, Bacterial ghosts are an efficient delivery system for DNA vaccines, J Immunol, 172, 6858, 10.4049/jimmunol.172.11.6858 Bae, 2004, Features of bacterial cellulose synthesis in a mutant generated by disruption of the diguanylate cyclase 1 gene of Acetobacter xylinum BPR 2001, Appl Microbiol Biotechnol, 65, 315 Cazorla, 2008, Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi, Infect Immun, 76, 324, 10.1128/IAI.01163-07 Hermans, 2004, The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo, J Immunol Methods, 285, 25, 10.1016/j.jim.2003.10.017 Lavelle, 2005, Generation of improved mucosal vaccines by induction of innate immunity, Cell Mol Life Sci, 62, 2750, 10.1007/s00018-005-5290-1 Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588 Nimmerjahn, 2005, Divergent immunoglobulin g subclass activity through selective Fc receptor binding, Science, 310, 1510, 10.1126/science.1118948 Stavnezer, 1995, Regulation of antibody production and class switching by TGF-beta, J Immunol, 155, 1647, 10.4049/jimmunol.155.4.1647 Mosmann, 1989, TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu Rev Immunol, 7, 145, 10.1146/annurev.iy.07.040189.001045 Kawaguchi, 2004, IL-17 cytokine family, J Allergy Clin Immunol, 114, 1265, 10.1016/j.jaci.2004.10.019 Kawaguchi, 2004, Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway, J Allergy Clin Immunol, 114, 444, 10.1016/j.jaci.2004.03.047 Kolls, 2004, Interleukin-17 family members and inflammation, Immunity, 21, 467, 10.1016/j.immuni.2004.08.018 Kelly, 2005, Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection, Infect Immun, 73, 617, 10.1128/IAI.73.1.617-621.2005 Sullivan, 2006, Noninvasive delivery technologies: respiratory delivery of vaccines, Expert Opin Drug Deliv, 3, 87, 10.1517/17425247.3.1.87 Witowski, 2004, Interleukin-17: a mediator of inflammatory responses, Cell Mol Life Sci, 61, 567, 10.1007/s00018-003-3228-z Zou, 2002, Cytokines in the generation and maturation of dendritic cells: recent advances, Eur Cytokine Netw, 13, 186 Clive, 2010, Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?, Expert Rev Vaccines, 9, 519, 10.1586/erv.10.40 Pearson, 2001, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr Rev, 22, 153 Lillard, 2001, RANTES potentiates antigen-specific mucosal immune responses, J Immunol, 166, 162, 10.4049/jimmunol.166.1.162 Siegrist, 2007, Mechanisms underlying adverse reactions to vaccines, J Comp Pathol, 137, S46, 10.1016/j.jcpa.2007.04.012 Menten, 2002, Macrophage inflammatory protein-1, Cytokine Growth Factor Rev, 13, 455, 10.1016/S1359-6101(02)00045-X Stuart, 2008, CCL3 protects mice from corneal pathology during recurrent HSV-1 infection, Front Biosci, 13, 4407, 10.2741/3013 Sonnenberg, 2010, Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces, Adv Immunol, 107, 1, 10.1016/B978-0-12-381300-8.00001-0 Ouyang, 2011, Regulation and functions of IL-10 family cytokines in inflammation and diseases, Annu Rev Immunol, April (29), 71, 10.1146/annurev-immunol-031210-101312 Kolls, 2010, The role of Th17 cytokines in primary mucosal immunity, Cytokine Growth Factor Rev, 21, 443, 10.1016/j.cytogfr.2010.11.002 Lin, 2010, Th17 cytokines and vaccine-induced immunity, Semin Immunopathol, 32, 79, 10.1007/s00281-009-0191-2 McWhirter, 2009, A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP, J Exp Med, 206, 1899, 10.1084/jem.20082874